Overall market sentiment has been down on Adaptimmune Therapeutics PLC - ADR (ADAP) stock lately. ADAP receives a Bearish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With ADAP Stock Today?
Adaptimmune Therapeutics PLC - ADR (ADAP) stock is trading at $7.82 as of 1:59 PM on Thursday, Sep 24, a drop of -$0.13, or -1.64% from the previous closing price of $7.95. The stock has traded between $7.37 and $7.98 so far today. Volume today is 526,268 compared to average volume of 678,982.
To see InvestorsObserver's Sentiment Score for Adaptimmune Therapeutics PLC - ADR click here.
More About Adaptimmune Therapeutics PLC - ADR
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
Click Here to get the full Stock Score Report on Adaptimmune Therapeutics PLC - ADR (ADAP) Stock.
